eComment: Brain natriuretic peptide is removed by continuous veno-venous hemofiltration in pediatric patients

2009 ◽  
Vol 9 (1) ◽  
pp. 36-36
Author(s):  
L. A. Bockeria ◽  
M. Yarustovsky
Keyword(s):  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Pediatric Patients

scholarly journals Brain natriuretic peptide is removed by continuous veno-venous hemofiltration in pediatric patients

2009 ◽  
Vol 9 (1) ◽  
pp. 33-36 ◽  
Author(s):  
Z. Ricci ◽  
C. Garisto ◽  
S. Morelli ◽  
L. Di Chiara ◽  
C. Ronco ◽  
...  
Keyword(s):  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Pediatric Patients

scholarly journals Brain Natriuretic Peptide Levels in Managing Pediatric Patients With Pulmonary Arterial Hypertension

CHEST Journal ◽  
2009 ◽  
Vol 135 (3) ◽  
pp. 745-751 ◽  
Author(s):  
Anna Bernus ◽  
Brandie D. Wagner ◽  
Frank Accurso ◽  
Aimee Doran ◽  
Heidi Kaess ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Pediatric Patients ◽  
Pulmonary Arterial

N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability

2006 ◽  
Vol 44 (1) ◽  
Author(s):  
Stefanie Albers ◽  
Thomas S. Mir ◽  
Munif Haddad ◽  
Stephanie Läer
Keyword(s):  
Heart Disease ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Pediatric Patients ◽  
Pediatric Population ◽  
Method Comparison ◽  
Normal Ranges ◽  
Interlaboratory Variability ◽  
Percentile Curve

AbstractThe aim of the present study was the investigation of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the pediatric population. This is essential for adequate monitoring and classification of pediatric patients with heart disease, but no consistent data are available yet. In addition, the comparability of two commercially available NT-proBNP assays and the inter-laboratory variability for the most suitable one were assessed. For this purpose, 408 subjects (1–29years) were included. NT-proBNP was determined with a non-competitive electrochemiluminescent immunoassay (Roche NT-proBNP; n=402) and a competitive enzyme-immunoassay (Biomedica NT-proBNP; n=402). Inter-laboratory variability was evaluated for the Roche assay by stepwise inclusion of four and 11 centers throughout Germany, respectively. Roche NT-proBNP ranged from 5.0 to 391.5ng/L, with higher values for younger children. The 97.5th (75th) percentile curve ranged from 319.9ng/L (231.2 ng/L, 1–3years) to 114.9ng/L (53.3 ng/L, 18years). In contrast, Biomedica NT-proBNP ranged from 253.7 to 7602.8 ng/L, with no significant age dependency. The mean difference between the assays was 1649.7ng/L (95% confidence interval 1546.3–1753.1ng/L). Inter-laboratory variability ranged from 6.5% to 3.8%, covering a range from 51.3 to 6618.1ng/L. The assay seems to influence the interpretation of resulting NT-proBNP values and therefore has to be chosen carefully. For the monitoring and classification of pediatric patients with congenital heart disease, age-based NT-proBNP values should be used.

Brain Natriuretic Peptide: It’s Not About the Brain or Just Another Smart Polypeptide—It’s About the Heart

2015 ◽  
Vol 34 (6) ◽  
pp. 355-360
Author(s):  
Dominick M. Carella
Keyword(s):  
Heart Failure ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Congenital Heart ◽  
Pediatric Patients ◽  
Ductus Arteriosus ◽  
Predictive Biomarker ◽  
Diagnostic Role ◽  
The Brain

AbstractBrain natriuretic peptide (BNP) is a cardiac hormone with diuretic, natriuretic, and vasodilator properties. Measurement of plasma B-type natriuretic peptide concentrations is increasingly used to aid diagnosis, assess prognosis, and tailor treatment in adults with congestive heart failure. Recent studies suggest that the peptide is also useful in pediatric patients. The diagnostic role of plasma BNP in neonates admitted to the NICU has shown promise as an aid in diagnosis in neonates with signs of congenital heart disease; as a biomarker of bronchopulmonary dysplasia, patent ductus arteriosus, and persistent pulmonary hypertension of the newborn; a predictive biomarker of the response to indomethacin in preterm infants; and, more significantly, in acute heart failure.

1518: Troponin T and N-Terminal Pro-Brain Natriuretic Peptide (PRO-BNP) Changes in Patients Undergoing Transurethral Resection of The Prostate (TURP)

2004 ◽  
Vol 171 (4S) ◽  
pp. 399-400
Author(s):  
Ramaswamy Manikandan ◽  
Calvin Nathaniel ◽  
Ravi Gullipalli ◽  
Adebanji Adeyoju ◽  
Stephen C.W. Brown ◽  
...  
Keyword(s):  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Transurethral Resection ◽  
Troponin T
Sign in / Sign up

Export Citation Format

Share Document